Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Pulmonology

Background:

• Ventilator-associated pneumonia (VAP) is a significant cause of morbidity and mortality in mechanically ventilated ICU patients.
• Ventilator-associated tracheobronchitis (VAT) was historically viewed as a precursor to VAP.
• Emerging evidence suggests VAT may be an independent risk factor for increased morbidity and mortality.

Purpose of the Study:

• To differentiate VAT from VAP and clarify their respective impacts on patient outcomes.
• To review current treatment strategies for VAP and VAT, particularly the role of inhaled antibiotics.

Main Methods:

• Review of recent clinical data and literature on VAP and VAT.
• Analysis of treatment outcomes for VAP and VAT using different antibiotic approaches.

Main Results:

• VAT may represent a distinct clinical entity, contributing to mortality independently of VAP.
• Inhaled antibiotics are increasingly used for salvage therapy in VAP caused by multidrug-resistant Gram-negative bacteria.
• VAT shows effective treatment response to inhaled antibiotics alone or in combination with systemic antimicrobials.

Conclusions:

• VAT should be considered a separate entity from VAP, with its own implications for patient morbidity and mortality.
• Treatment strategies for VAT can differ from VAP, with inhaled antibiotics playing a potentially primary role.
• Further research is warranted to fully elucidate the pathophysiology and optimal management of VAT.